Investment Rating - The industry investment rating is "Increase" (maintained) [9] Core Viewpoints - The report highlights the approval of China's first CaHA facial filler, Aphranel® by Moyang Bio, which is expected to perform well in the market due to its innovative micro-sphere structure and high biocompatibility [2] - Jinbo Bio reported a significant revenue increase of 85.40% year-on-year, reaching 1.447 billion yuan, with a net profit growth of 144.65% to 733 million yuan, driven by new product development and market expansion [3][4] - The report emphasizes the long-term potential for medical aesthetics penetration to continue increasing, suggesting a focus on companies like Giant Bio, Jinbo Bio, and others in the sector [9] Summary by Sections New Product Approvals - The report discusses the approval of Aphranel® as the first CaHA injection in China, noting its superior clinical performance and safety profile [2] - Jinbo Bio launched the world's first collagen net product, targeting eye area rejuvenation through advanced technology [4] Financial Performance - Jinbo Bio's financial results for 2024 show a revenue of 1.447 billion yuan, marking an 85.40% increase, and a net profit of 733 million yuan, reflecting a 144.65% growth [3] Market Trends - The report indicates a growing trend in the medical aesthetics market, with an expectation for increased penetration rates and competitive dynamics among brands [9] - It highlights the differentiation in cosmetic channels and the competitive landscape, suggesting that leading domestic brands are likely to continue outperforming [9]

Investment Rating - The investment rating for the social services industry is "Positive" (maintained) [1] Core Insights - The report highlights the strong performance of Ctrip, which achieved revenue of 12.8 billion yuan in Q4 2024, representing a year-on-year increase of 23.5%, slightly exceeding Bloomberg's consensus forecast [9] - The report emphasizes the growth of the creator economy, driven by the proliferation of digital content platforms and AI productivity tools, which have lowered the barriers to entry for content creation [19][21] - The IP and apparel sector is experiencing a transformation, with leading companies moving from product-centric models to lifestyle branding, unlocking significant market potential [29][33] Summary by Sections Travel and Tourism - Ctrip's revenue from accommodation booking, transportation ticketing, vacation travel, and business travel management reached 5.2 billion, 4.8 billion, 0.9 billion, and 0.7 billion yuan respectively, with year-on-year growth rates of 33%, 16%, 24%, and 5% [9][12] - The company is increasing its international business investments, with overseas hotel and flight bookings growing over 70% year-on-year [11] Creator Economy - The creator economy is expanding rapidly, with active creators on content platforms increasing by 62% year-on-year, particularly on WeChat Video and Douyin [21] - AI tools are enhancing content production efficiency, allowing non-professionals to participate in content creation [26][28] IP and Apparel - The global IP licensing market reached $356.5 billion in 2023, with apparel being the largest category at 14.3% [33][37] - In China, the IP licensing market grew to $13.77 billion in 2023, surpassing Germany to become the fourth-largest market globally [38] Company Performance - The report notes that the same-store sales for Mixue Ice City reached 143,000 yuan in January 2025, a year-on-year increase of 17.4%, indicating strong operational resilience [47] - Mixue Ice City is expanding its product offerings and has established a significant presence in Southeast Asia, with over 4,800 stores [57]

Core Viewpoint - The article highlights a significant shift in fund managers' investment strategies towards the Hong Kong consumer sector, driven by extreme undervaluation and a strong demand for reallocation after a period of severe sell-off in consumer stocks [1][2][6]. Group 1: Market Dynamics - The recent IPO of major milk tea brands like Gu Ming and Mi Xue Bing Cheng has sparked renewed interest in the Hong Kong consumer market, with Mi Xue Bing Cheng achieving a record subscription amount of HKD 1.83 trillion, reflecting a 5266 times oversubscription [2][4]. - Fund managers are increasingly optimistic about consumer stocks, as evidenced by the dramatic price increases of stocks like Nai Xue's Tea, which surged over 80% in just two days following the IPO news [2][3]. Group 2: Fund Manager Behavior - Fund managers have been actively reallocating their portfolios, moving from technology stocks to consumer stocks, as they seek to balance their positions and capitalize on the emerging opportunities in the consumer sector [5][6]. - The article notes that many previously high-weighted consumer stocks have been sold off to the point of being excluded from major fund portfolios, indicating a significant shift in investment focus [4][5]. Group 3: Valuation and Future Expectations - The decline in consumer stock valuations at the end of last year, exacerbated by the tech sector's performance, has created a favorable environment for fund managers to invest in consumer stocks, anticipating a rebound in consumer demand by 2025 [6][7]. - Fund managers are focusing on companies with solid fundamentals and attractive valuations, particularly in traditional consumer sectors like liquor, home appliances, and brand-name Chinese medicine, as they expect improved performance in the consumer market [7][6].

Financial Performance - Revenue for the first half of 2024 reached RMB 2.54 billion, a year-on-year increase of 58.2%[7] - Adjusted profit for the first half of 2024 was RMB 1.03 billion, a year-on-year increase of 51.8%[9] - Total revenue for the first half of 2024 reached RMB 2,540.4 million, a 58.2% increase compared to RMB 1,605.7 million in the same period of 2023[23] - Total revenue for the first half of 2024 reached RMB 2,540.4 million, a 58.2% increase compared to RMB 1,605.7 million in the same period of 2023[24] - Revenue from professional skincare products accounted for 99.7% of total revenue, with functional skincare contributing RMB 1,939.6 million (76.4%) and medical dressings contributing RMB 592.2 million (23.3%)[24] - Revenue for the first half of 2024 reached RMB 2,540.4 million, a 58.2% increase compared to RMB 1,605.7 million in the same period of 2023[70] - Gross profit for the first half of 2024 was RMB 2,093.2 million, up 54.9% from RMB 1,351.0 million in the first half of 2023[70] - Net profit attributable to owners of the company for the first half of 2024 was RMB 983.2 million, a 47.4% increase from RMB 666.9 million in the same period of 2023[70] - Revenue from customer contracts increased to RMB 2,540,432 thousand in the first half of 2024, up from RMB 1,605,698 thousand in the same period of 2023, representing a growth of 58.2%[85] - Basic earnings per share for 2024 were RMB 983,164 thousand, up from RMB 666,940 thousand in 2023, a 47.4% increase[97] R&D and Innovation - R&D expenditure for the first half of 2024 was RMB 49 million, a year-on-year increase of 43.2%, accounting for 1.9% of revenue[10] - The company has over 100 ongoing R&D projects as of the end of the reporting period[10] - The company has been granted and applied for 133 patents, with 40 new patents added during the reporting period[10] - The company participated in multiple academic conferences to promote the development of recombinant collagen technology[14] - R&D expenses increased by 43.2% YoY to RMB 48.7 million, representing 1.9% of revenue[34] - R&D costs surged to RMB 13,469 thousand in 2024 from RMB 1,290 thousand in 2023, a 944.1% increase[91] - 11% of the net proceeds from the global offering are allocated for R&D investment, including expanding the R&D team and facilities[64] Brand Performance - Reborn Beauty brand achieved revenue of RMB 2.071 billion, a year-on-year increase of 68.6%[12] - Reborn Beauty's Human-like Recombinant Collagen Essence became the company's top star product, ranking No.1 in multiple categories during the 618 promotion[12] - Reborn Beauty launched the new Focus Series, with the Focus Cream ranking No.1 in Tmall's new cream list and Douyin's collagen cream popularity list during 618[12] - Reborn Beauty's Order Spot Stick ranked No.1 in Tmall's new repair essence list during 618, completing the oil-control and acne-treatment product portfolio[12] - Kelisheng brand achieved revenue of RMB 396 million, a year-on-year increase of 23.6%[13] - Kelisheng's new Vitality Series products, including eye cream and face cream, received a 99% positive rating and a score of 4.64 in consumer trials[13] - The Kefumei brand contributed RMB 2,070.9 million (81.5%) to total revenue, a 68.6% increase compared to the same period in 2023[32] - The Kelijin brand generated RMB 396.1 million (15.6%) in revenue, a 23.6% increase year-over-year[32] - Other brands contributed RMB 64.9 million (2.6%) to total revenue, a 40.8% increase compared to the same period in 2023[32] - Revenue from the professional skincare product "Kefumei" increased by 68.6% YoY to RMB 2,070.9 million, accounting for 81.5% of total revenue[33] - Revenue from the skincare product "Keling" rose by 23.6% YoY to RMB 396.1 million, contributing 15.6% of total revenue[33] Marketing and Sales - The company launched new products and continued to optimize its product matrix to reach a broader customer base[11] - The company strengthened public domain marketing, with Reborn Beauty's Focus Cream campaign generating over 200 million topic exposures on Xiaohongshu[15] - Reborn Beauty appointed Olympic swimming champion Ye Shiwen as its brand ambassador to enhance consumer emotional connection[15] - Reborn Beauty launched a special 520 campaign with limited edition "Lucky Stick" products to strengthen brand-consumer interaction[15] - Direct sales channel revenue accounted for 72.4% of total revenue at RMB 1,838 million, while distribution channel revenue was RMB 702 million, representing 27.6% of total revenue[18] - The company expanded its offline presence with approximately 10 offline stores in key cities, including the flagship store in Chongqing opened on June 16, 2024[17] - The company's products are available in approximately 1,500 public hospitals, 2,700 private hospitals and clinics, 650 chain pharmacies, and 6,000 CS/KA stores[17] - Online GMV growth for the Keruimei and Kelijing brands exceeded 60% and 100% respectively during the 618 shopping festival in 2024[17] - Direct-to-consumer (DTC) online sales through the company's own stores reached RMB 1,603.2 million, a 64.1% year-over-year increase, accounting for 63.1% of total revenue[26][27] - Online sales through e-commerce platforms grew 143.3% year-over-year to RMB 167.4 million, representing 6.6% of total revenue[29] - Offline direct sales increased by 82.2% year-over-year to RMB 67.6 million, accounting for 2.7% of total revenue[30] - Sales to distributors grew 34.4% year-over-year to RMB 702.3 million, representing 27.6% of total revenue[31] - The company's offline advertising campaigns covered major transportation hubs and commercial centers in cities like Xi'an, Chongqing, and Wuhan[17] - Marketing and promotion expenses rose to RMB 811,642 thousand in 2024 from RMB 521,705 thousand in 2023, a 55.6% increase[90] Production and Operations - The company added 1 new cosmetics production line and 1 medical device production line, with a new medical device factory expected to be operational within the year[19] - The company's capital commitments primarily consist of plant, machinery, and buildings, amounting to RMB 239.8 million as of June 30, 2024[39] - The company recorded capital expenditures of RMB 164.7 million in the six months ended June 30, 2024, mainly for the construction of new factories and the purchase of production line equipment[39] - The company has 1,512 full-time employees as of June 30, 2024, with 39.9% in production, 11.6% in R&D, 30.0% in sales and marketing, and 18.5% in general and administrative functions[40][41] - Inventory grew by 66.5% to RMB 333.7 million as of June 30, 2024, from RMB 200.4 million as of December 31, 2023[71] - Inventory increased by RMB 133,274 thousand, reflecting higher stock levels compared to the previous year[76] - Inventory, consumables, and custom product costs increased to RMB 314,231 thousand in 2024 from RMB 199,527 thousand in 2023, a 57.4% increase[90] - The company's investment in property, plant, and equipment decreased to RMB 165,417 thousand in 2024, down from RMB 186,961 thousand in 2023[77] - The company's net cash used in investing activities decreased to RMB 343,498 thousand in 2024, compared to RMB 472,404 thousand in 2023[77] - The company acquired assets worth RMB 284,042 thousand in 2024, compared to RMB 111,910 thousand in 2023, a 153.8% increase[98] Financial Position and Capital - Total assets as of June 30, 2024, were RMB 7.78 billion, a 56.5% increase compared to the end of 2023[8] - Total liabilities as of June 30, 2024, were RMB 1.81 billion, a 200% increase compared to the end of 2023[8] - Net current assets as of June 30, 2024, were RMB 4.93 billion, a 36.8% increase compared to the end of 2023[8] - The company's cash and cash equivalents increased by 82.3% to RMB 4,564.4 million as of June 30, 2024, compared to RMB 2,504.0 million as of December 31, 2023[39] - Cash and cash equivalents as of June 30, 2024, stood at RMB 4,564.4 million, an 82.3% increase from RMB 2,504.0 million as of December 31, 2023[71] - The company's cash and cash equivalents increased significantly to RMB 4,564,386 thousand as of June 30, 2024, up from RMB 1,557,509 thousand in the same period of 2023[77] - Net asset value increased to RMB 5,974,848 thousand as of June 30, 2024, up from RMB 4,371,050 thousand at the end of 2023[73] - The company issued shares worth RMB 1,498,500 thousand, resulting in a total equity increase of RMB 1,498,502 thousand[74] - The company declared dividends of RMB 908,437 thousand for the 2023 final and special dividends[74] - The company declared a total dividend of RMB 908,437 thousand for 2023, including a final dividend of RMB 449,536 thousand and a special dividend of RMB 458,901 thousand[94] - The company completed a share placement and subscription, raising approximately HKD 1,627 million (net of commissions and estimated expenses), with 90% (HKD 1,464.3 million) allocated for core business development and ecosystem layout, and 10% (HKD 162.7 million) for working capital and general corporate purposes[67] - The company issued 33,220,000 ordinary shares at a subscription price of HKD 49.40 per share (equivalent to RMB 45.11 per share), raising a total of HKD 1,641,065,000 (RMB 1,498,500,000 before deducting share issuance costs)[104] Corporate Governance and Shareholding - The company has adopted a Restricted Stock Unit (RSU) plan, with a maximum of 19,000,000 shares, representing approximately 1.85% of the total issued share capital as of the reporting date[41] - The company has adopted the 2023 Share Option Plan and the 2023 Share Award Plan, with a maximum of 99,500,000 shares, representing 9.68% of the total issued share capital as of the reporting date[42] - The company has decided not to declare an interim dividend for the six months ended June 30, 2024[43] - The company has not separated the roles of Chairman and CEO, with Mr. Yan Jianya holding both positions, which the company believes is beneficial for consistent leadership and effective execution of business strategies[43] - Mr. Yan Jianya holds 589,350,972 shares, representing 57.32% of the company's total issued shares as of June 30, 2024[46] - Ms. Ye Juan holds 1,049,800 shares, representing 0.10% of the company's total issued shares as of June 30, 2024[46] - Ms. Fang Juan holds 1,157,601 shares, representing 0.11% of the company's total issued shares as of June 30, 2024[46] - Ms. Zhang Huijuan holds 1,240,000 shares, representing 0.12% of the company's total issued shares as of June 30, 2024[46] - Dr. Fan holds 581,104,935 shares through controlled corporations, representing 56.52% of the company's total issued shares as of June 30, 2024[50] - Healing Holding, wholly owned by Dr. Fan, holds 900,000 shares, representing 0.09% of the company's total issued shares as of June 30, 2024[50] - E Fund Management Co., Ltd. holds 50,067,000 shares, representing 4.87% of the company's total issued shares as of June 30, 2024[51] - The company did not purchase, sell, or redeem any of its listed securities during the reporting period[52] - The restricted share unit plan has a remaining term of 7 years, with a total duration of 10 years from the date of adoption by the board[53] - The maximum number of shares under the restricted share unit plan is 19,000,000, representing approximately 1.85% of the company's total issued share capital as of the report date[54] - The restricted share units are granted at prices of RMB 4.74 per share (granted on December 8, 2021) and RMB 20 per share (granted on September 26, 2022)[53] - The restricted share units are expected to vest in five equal installments, with 20% of the total shares vesting every 12 months from the grant date[54] - As of June 30, 2024, the company's chairman, executive director, and CEO holds 10,459,502 restricted shares, representing 1.02% of the total issued shares[55] - A total of 13,361,601 restricted shares remain unvested and subject to lock-up conditions as of June 30, 2024[55] - The restricted share unit plan aims to align the interests of shareholders and employees, and to attract and retain senior management and core talent[53] - The company adopted a fourth amended and restated memorandum and articles of association on June 13, 2024, to comply with the Listing Rules regarding electronic dissemination of corporate communications[53] - No further restricted share units will be granted under the plan after the company's listing[54] - The restricted share unit plan was fully granted before the company's listing, with no additional units to be issued post-listing[54] - The maximum number of shares that can be issued under the 2023 Plan is 99,500,000 shares, representing 9.68% of the total issued shares (excluding treasury shares) as of the report date[57] - The maximum number of shares that can be issued to service provider participants under the 2023 Plan is 19,900,000 shares, representing 1.94% of the total issued shares (excluding treasury shares) as of the report date[57] - The 2023 Plan aims to provide participants with personal equity interests in the company to recognize, incentivize, and reward them, attract and retain the most qualified personnel, and drive the group's business success[57] - The minimum vesting period for options or award shares is generally 12 months, but the board may grant shorter vesting periods under certain circumstances[58] - The 2023 Plan has a remaining validity period of 9 years from the adoption date[60] - The company granted a total of 20,000,000 options to 128 eligible participants on December 28, 2023, to subscribe for ordinary shares with a par value of $0.00001 per share[60] - No share awards have been granted under the 2023 Share Award Plan as of the report date[60] - The exercise price of options must be at least the higher of the closing price on the offer date, the average closing price over the 5 business days prior to the offer date, or the par value per share on the grant date[60] - The company granted a total of 20,000,000 share options on December 28, 2023, with 40% vesting after one year, 30% after two years, and the remaining 30% after three years[62] - The exercise price of the granted share options is HK$35.05 per share, with a fair value of HK$6.25 per share at the grant date, totaling HK$125 million[62] - The company approved a Restricted Share Unit Plan on December 8, 2021[122] - The company's shares have a par value of $0.00001 per share[123] - The company operates under the Securities and Futures Ordinance (Chapter 571 of Hong Kong Law)[122] - The company's shares are held by shareholders[123] - The company has subsidiaries as defined under Section 15 of the Companies Ordinance[123] - The company's operations are subject to the jurisdiction of the United States, its territories, and all areas under its jurisdiction[123] - The company's financial reporting is in US dollars, the legal currency of the United States[124] Social Responsibility and Donations - The company donated over RMB 5 million worth of products to frontline educators and medical workers during the "March 8th Warm Spring Love Action"[20] - The company launched the "Giant 315 Transparency Commitment" on March 15, 2024, to promote transparency in the recombinant collagen industry[21] Industry Recognition and Achievements - The company was recognized as the global leader in recombinant collagen by Euromonitor International[9] Strategic Investments and Future Plans - The company plans to continue R&D investment, enrich raw material reserves, and expand product lines in the second half of 2024[20

Financial Performance - Revenue for the six months ended June 30, 2024, reached RMB 2,540.4 million, representing a 58.2% increase compared to RMB 1,605.7 million in the same period of 2023[2] - Gross profit for the same period was RMB 2,093.2 million, up 54.9% from RMB 1,351.0 million year-over-year[2] - Net profit attributable to shareholders was RMB 983.2 million, reflecting a 47.4% increase from RMB 666.9 million in the prior year[2] - Adjusted net profit (non-IFRS measure) for the period was RMB 1,026.6 million, a 51.8% increase compared to RMB 676.4 million in 2023[2] - Basic earnings per share increased to RMB 0.99, up 47.8% from RMB 0.67 in the previous year[4] - The total comprehensive income for the period was RMB 982.1 million, compared to RMB 666.0 million in the same period last year[4] - The company reported a pre-tax profit of RMB 1,155.2 million, which is a 49.0% increase from RMB 775.6 million in 2023[3] - The total tax expense for the period amounted to RMB 174.64 million, compared to RMB 109.56 million in the previous year[24] - Profit for the six months ended June 30, 2024, was RMB 980.6 million, representing a 47.2% increase from RMB 666.0 million for the same period in 2023[88] Assets and Liabilities - Non-current assets increased to RMB 1,092,431 thousand as of June 30, 2024, compared to RMB 837,999 thousand as of December 31, 2023, reflecting a growth of 30.4%[6] - Current assets rose significantly to RMB 6,688,210 thousand, up from RMB 4,135,079 thousand, marking an increase of 61.8%[6] - Total liabilities increased to RMB 1,805,793 thousand, up from RMB 1,061,228 thousand, indicating a rise of 70.0%[7] - The net asset value reached RMB 5,974,848 thousand, compared to RMB 4,371,050 thousand, showing an increase of 36.7%[7] - The company’s total equity increased to RMB 5,974,848 thousand, compared to RMB 4,371,050 thousand, indicating a growth of 36.7%[7] - The company’s non-current liabilities decreased to RMB 50,146 thousand from RMB 71,416 thousand, a reduction of 29.8%[7] Revenue Sources - Customer contract revenue for the six months ended June 30, 2024, was RMB 2,540,432 thousand, representing a 58% increase from RMB 1,605,698 thousand in the same period of 2023[17] - Revenue from professional skin care products reached RMB 1,939.6 million, accounting for 76.4% of total revenue, up from 74.5% in the previous year[63] - Revenue from health food and other products was RMB 8.6 million, representing 0.3% of total revenue, down from 0.7% in the previous year[63] - Revenue from the Kewemi brand was RMB 2,070.9 million, a 68.6% increase year-over-year, accounting for 81.5% of total revenue[73] - Revenue from the Keli Jin brand was RMB 396.1 million, a 23.6% increase year-over-year, representing 15.6% of total revenue[75] Expenses - Sales and distribution expenses for the period were RMB 892.0 million, compared to RMB 555.2 million in the previous year[3] - Research and development expenses for the period were RMB 1,338.0 million, reflecting the company's commitment to innovation[3] - The group reported a significant increase in employee benefits expenses, including salaries and wages, which rose to RMB 81,757 thousand from RMB 51,819 thousand in the previous year[21] - Administrative expenses for the six months ended June 30, 2024, were RMB 65.7 million, an increase of 38.3% compared to RMB 47.5 million for the same period in 2023, primarily due to increased employee compensation from a rise in management personnel[85] - Total sales cost for the six months ended June 30, 2024, was RMB 447.2 million, a 75.6% increase from RMB 254.7 million in the same period of 2023[78] Market Strategy and Development - The company plans to continue expanding its market presence and investing in new product development to sustain growth[2] - The company continues to focus on R&D for new technologies and products, aiming to expand its market presence and optimize channel operations[36] - The company is focused on developing a comprehensive skincare solution with a series of new products set to launch in the coming months[44] - The company has launched a new "Focus Series" targeting skin conditions caused by lifestyle factors, with the first product achieving top rankings in e-commerce during promotional events[44] - The company continues to enhance its product matrix and expand its market presence through innovative marketing strategies and new product launches[40] Corporate Governance and Compliance - The company has committed to high standards of corporate governance, adhering to all applicable codes except for a deviation regarding the separation of the roles of Chairman and CEO[109][111] - The company has confirmed compliance with the standard code for securities trading by all directors during the reporting period[112] - The company has not engaged in any purchase, sale, or redemption of its listed securities during the reporting period[108] Social Responsibility - The company actively participates in social responsibility initiatives, donating over RMB 5 million in products to support education workers and medical personnel[58] - The company initiated a bottle recycling program to advocate for sustainable development and engage consumers in environmental protection[50] Future Plans and Investments - The company plans to enhance R&D efforts and expand product offerings in the second half of 2024, focusing on new products and marketing strategies[61] - There are no significant future plans for major investments or acquisitions as of June 30, 2024[95]

Financial Performance - Revenue for 2023 reached RMB 3,524.1 million, a 49.0% increase from RMB 2,364.4 million in 2022[7] - Gross profit for 2023 was RMB 2,947.1 million, reflecting a 47.7% growth compared to RMB 1,995.2 million in 2022[7] - Net profit for 2023 amounted to RMB 1,448.2 million, up 44.6% from RMB 1,001.6 million in 2022[7] - Pre-tax profit for 2023 was RMB 1,745.1 million, a 48.2% increase from RMB 1,177.7 million in 2022[7] - Adjusted net profit for 2023 (non-IFRS measure) was RMB 1,468.7 million, a 39.0% increase from RMB 1,056.4 million in 2022[7] - Total revenue for the year ended December 31, 2023, was RMB 3,524.1 million, a 49.0% increase from RMB 2,364.4 million in 2022[34] - Total revenue for 2023 was RMB 3,524.1 million, up 48.9% from RMB 2,364.4 million in 2022[42] - Gross profit for 2023 was RMB 2,947.1 million, a 47.7% increase from RMB 1,995.2 million in 2022, with a gross margin of 83.6%[48] - Basic earnings per share rose by 50.5% to RMB 1.49 in 2023, compared to RMB 0.99 in 2022[56] Research and Development - Research and development investment increased by 70% year-on-year in 2023, with 93 patents granted or pending[10] - Research and development expenses amounted to RMB 750 million, a 70.5% increase year-on-year, accounting for 2.1% of revenue[15] - The company holds 93 authorized and pending patents, with 13 new patents added during the reporting period[16] - The company plans to increase R&D investment in 2024 to enhance product categories and clinical approval for medical devices[33] - The company is investing in R&D for new technologies, with a budget allocation of $10 million for the upcoming year[149] Sales and Distribution - Direct sales channel revenue grew over 70% year-on-year, with 4,000 offline locations and over 6,000 supermarkets entered[11] - Direct sales revenue amounted to RMB 2,420.5 million, accounting for 68.7% of total revenue, with a year-on-year increase of 9.4 percentage points[29] - Revenue from professional skincare products reached RMB 2,647.3 million, accounting for 75.1% of total revenue, up from 66.0% in 2022[35] - Revenue from sales to distributors was RMB 1,103.6 million, a 14.6% increase, making up 31.3% of total revenue[40] - Revenue from online direct sales on e-commerce platforms increased by 42.7% to RMB 177.5 million, accounting for 5.0% of total revenue[38] - Offline direct sales revenue rose by 39.6% to RMB 88.5 million, representing 2.5% of total revenue[39] Brand Performance - The Kefu Mei brand generated nearly RMB 2.8 billion in revenue, growing over 70% year-on-year[14] - Brand revenue for 可复美 reached RMB 2,788.3 million, representing a 72.9% increase compared to the same period in 2022[22] - 可丽金 achieved brand revenue of RMB 616.6 million, remaining flat compared to the same period in 2022[24] - During the 618 shopping festival, 可复美 and 可丽金's online GMV growth exceeded 165% and 70% respectively, while during the Double Eleven festival, growth exceeded 100% and 50% respectively[29] Corporate Governance - The company is committed to high standards of corporate governance to protect shareholder interests[153] - The board consists of executive directors and independent non-executive directors, ensuring compliance with listing rules regarding independence[156][157] - The company has adopted the corporate governance code as per the listing rules and has complied with all applicable provisions during the reporting period, except for a deviation regarding the separation of roles between the chairman and CEO[153][159] - The company has established a board diversity policy that considers various diversity indicators, including gender, age, cultural background, and professional qualifications[185] Employee Management - As of December 31, 2023, the company had a total of 1,164 full-time employees, with 33.8% in production, 14.2% in R&D, 33.5% in sales and marketing, and 18.5% in general and administration[108] - The company has implemented a comprehensive training program for new and existing employees to ensure competency in their roles[108] - The company aims to recruit employees with relevant educational backgrounds or industry experience through campus recruitment and experienced hiring[190] Future Outlook - Future outlook indicates a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion[149] - Plans for market expansion include entering three new international markets by Q4 2024, targeting a 20% increase in market share[149] - The company is considering strategic acquisitions to enhance its product portfolio, with potential targets identified in the biotech sector[149] Risk Management - The company faces various operational risks, including changes in the regulatory environment in China and competition from other market participants[195] - The company has established a risk management and internal control system to address operational risks, which includes policies and procedures deemed suitable for its business operations[195] - The company conducts annual risk identification and assessment to improve its risk management system and may set occupational health and safety goals as needed[197] Awards and Recognition - The company received multiple quality and sustainability awards, including "National Quality Integrity Benchmark Enterprise" and "Green Factory of Shaanxi Province" in 2023[31] - The company has received multiple awards for technological innovation and contributions to the field, highlighting its commitment to excellence[151]

Revenue and Profit Growth - Revenue increased by 49.0% to RMB 3,524.1 million in 2023 compared to RMB 2,364.4 million in 2022[2] - Gross profit rose by 47.7% to RMB 2,947.1 million in 2023 from RMB 1,995.2 million in 2022[2] - Net profit attributable to owners of the parent company grew by 44.9% to RMB 1,451.8 million in 2023 from RMB 1,002.0 million in 2022[2] - Adjusted net profit (non-IFRS measure) increased by 39.0% to RMB 1,468.7 million in 2023 compared to RMB 1,056.4 million in 2022[2] - Basic earnings per share increased by 50.5% to RMB 1.49 in 2023 from RMB 0.99 in 2022[2] - Sales revenue reached RMB 3,524.1 million in 2023, a year-on-year increase of 49.0%[51] - Net profit for the year reached RMB 1,448.2 million, a year-on-year increase of 44.6%[51] - Total revenue for 2023 reached RMB 3,524.1 million, a 49.0% increase compared to RMB 2,364.4 million in 2022, driven by product expansion and enhanced marketing efforts[66] - Gross profit increased by 47.7% to RMB 2,947.1 million in 2023, with a gross margin of 83.6%, down from 84.4% in 2022[81] - Net profit for 2023 was RMB 1,448.2 million, a 44.6% increase compared to RMB 1,001.6 million in 2022[84] - Basic earnings per share increased by 50.5% to RMB 1.49 in 2023, compared to RMB 0.99 in 2022[84] Financial Position and Assets - Total assets increased to RMB 4,442.5 million in 2023 from RMB 2,857.3 million in 2022[5] - Cash and cash equivalents grew to RMB 2,503.9 million in 2023 from RMB 1,330.9 million in 2022[5] - Inventory levels rose to RMB 200,440 thousand in 2023, up from RMB 183,895 thousand in 2022, with a notable increase in finished goods from RMB 111,906 thousand to RMB 150,590 thousand[38] - Trade receivables and bills increased to RMB 102,029 thousand in 2023 from RMB 69,420 thousand in 2022, with trade receivables growing from RMB 56,247 thousand to RMB 81,690 thousand[39] - Prepayments, other receivables, and other assets decreased to RMB 53,835 thousand in 2023 from RMB 87,496 thousand in 2022, with a significant reduction in prepayments from RMB 63,245 thousand to RMB 29,248 thousand[42] - Financial assets measured at fair value through profit or loss increased to RMB 1,274,776 thousand in 2023 from RMB 865,973 thousand in 2022, reflecting a growth in financial product investments[43] - Cash and cash equivalents surged to RMB 2,503,999 thousand in 2023, nearly doubling from RMB 1,330,951 thousand in 2022, with RMB-denominated cash and bank balances reaching RMB 1,891,140 thousand[44] - The company's liquidity as of December 31, 2023, was RMB 2,504.0 million, an 88.1% increase compared to RMB 1,331.0 million as of December 31, 2022[90] - The company held RMB 2,250 thousand in fixed-income products from China Merchants Wealth Management, representing 0.05% of total assets[88] - Non-principal-guaranteed floating income wealth management products from Xi'an Bank and Chang'an Bank accounted for 6.47% and 6.47% of total assets, respectively, with fair values of RMB 321,996 thousand and RMB 321,712 thousand[88] Dividends and Shareholder Returns - The company proposed a final dividend of RMB 0.44 per share and a special dividend of RMB 0.45 per share[2] - The proposed final dividend for 2023 is RMB 0.44 per ordinary share, and a special dividend of RMB 0.45 per ordinary share is also proposed[33] - The company plans to pay a final dividend of RMB 0.44 per share and a special dividend of RMB 0.45 per share for the year ended December 31, 2023, subject to shareholder approval at the annual general meeting[105] - The record date for determining eligibility for the proposed final and special dividends is June 21, 2024, with share transfer registration suspended from June 19 to June 21, 2024[106] R&D and Product Development - R&D expenditure was RMB 75.0 million, a year-on-year increase of 70.5%, accounting for 2.1% of revenue[52] - The company has over 40 types of collagen molecules in its recombinant collagen protein library, leading the industry[52] - The company launched several self-developed raw materials, including rare ginsenoside CK monomer and a specialized collagen repair ingredient group[52] - The company plans to increase R&D investment in 2024 to advance new product development and expand its product portfolio, focusing on medical-grade skincare products[65] - The company's research on C5HA recombinant collagen protein was published in December 2023, using advanced technologies such as laser scanning confocal microscopy and two-photon excitation[59] Sales and Marketing Performance - Revenue from customer contracts increased to RMB 3,524,143 thousand in 2023, up from RMB 2,364,445 thousand in 2022[21] - Revenue from professional skincare products grew significantly, with functional skincare contributing RMB 2,647.3 million (75.1% of total revenue), up from RMB 1,561.6 million (66.0%) in 2022[68] - Online direct-to-consumer (DTC) sales through the company's own stores generated RMB 2,154.5 million, a 77.5% increase from 2022, accounting for 61.2% of total revenue[71] - Revenue from sales to distributors increased by 14.6% to RMB 1,103.6 million, representing 31.3% of total revenue in 2023[74] - Revenue from online sales through third-party e-commerce platforms grew by 42.7% to RMB 177.5 million, accounting for 5.0% of total revenue[72] - Offline direct sales increased by 39.6% to RMB 88.5 million, driven by expanded retail presence and enhanced in-store marketing activities[73] - The company's online and offline channel layout has expanded, with products entering approximately 1,500 public hospitals, 2,500 private hospitals and clinics, 650 chain pharmacy brands, and 6,000 CS/KA stores in China[60] - The company's direct sales channel revenue reached RMB 2,420.5 million, accounting for 68.7% of total revenue, with a year-on-year increase of 9.4 percentage points[61] - The company's e-commerce channels achieved rapid growth, with GMV growth rates for Kefumei and Kelijing exceeding 165% and 70% respectively during the 618 shopping festival, and exceeding 100% and 50% respectively during the Double 11 shopping festival[61] Brand Performance - The Kefumei brand achieved revenue of RMB 2,788.3 million, a year-on-year increase of 72.9%[56] - The Keliji brand achieved revenue of RMB 616.6 million, flat compared to the same period in 2022[57] - Revenue from the Kefumei brand reached RMB 2,788.3 million, a 72.9% increase year-over-year, accounting for 79.1% of total revenue in 2023[77] - Revenue from the Kelijing brand was RMB 616.6 million, remaining stable compared to 2022, accounting for 17.5% of total revenue in 2023[78] - Other brands generated RMB 103.2 million in revenue, a 14.2% increase year-over-year, accounting for 2.9% of total revenue in 2023[78] - Health food and other products revenue decreased by 62.4% to RMB 16.0 million, accounting for 0.5% of total revenue in 2023[79] Operational and Financial Commitments - Capital commitments for buildings and plant machinery increased to RMB 490,223 thousand in 2023, compared to RMB 335,563 thousand in 2022[50] - Capital commitments for the year ending December 31, 2023, totaled RMB 490.2 million, primarily for factory buildings, machinery, and equipment[91] - Capital expenditures for the year ending December 31, 2023, amounted to RMB 229.6 million, mainly for new factory construction and production line equipment purchases[91] - The company completed the expansion of its recombinant collagen protein fermentation workshop, adding 2 new production lines for recombinant collagen protein, 4 new production lines for cosmetic products, and 2 new production lines for medical device products[62] Corporate Governance and Compliance - The financial statements are prepared in accordance with the International Financial Reporting Standards (IFRS) and the disclosure requirements of the Hong Kong Companies Ordinance, using the historical cost convention except for financial assets measured at fair value through profit or loss[10] - The consolidated financial statements include the financial statements of the company and its subsidiaries for the year ended December 31, 2023, with subsidiaries' financial statements prepared using consistent accounting policies[11] - The company has adopted new and revised IFRS standards for the current year's financial statements, including amendments to IAS 1 and IAS 8, which clarify the distinction between changes in accounting estimates and changes in accounting policies[13] - The company has disclosed significant accounting policies in the financial statements, with no impact on the measurement, recognition, or presentation of any items in the financial statements due to the amendments[13] - No major financial impact is expected from the adoption of revised International Financial Reporting Standards (IFRS) in the future[16] - The company has no significant deferred tax assets or liabilities related to the International Accounting Standards (IAS) 12 amendments[14] - The company has consistently adhered to the Corporate Governance Code, except for a deviation from Code Provision C.2.1, where the roles of Chairman and CEO are not separated, currently held by Mr. Yan Jianya[99][100] - The company has fully complied with the Standard Code for Securities Transactions by Directors during the reporting period and up to the date of the results announcement[101] - The annual general meeting is scheduled for June 13, 2024, with share transfer registration suspended from June 7 to June 13, 2024[106] - The financial data in the performance announcement has been verified by the auditor, Ernst & Young, but no assurance opinion is provided[107] - The audit committee, composed of independent non-executive directors, has reviewed the annual results for the year ended December 31, 2023[108] - The annual results announcement and annual report are available on the Hong Kong Stock Exchange website and the company's website[109] - The board of directors includes executive directors and independent non-executive directors as of March 25, 2024[109] Other Income and Expenses - Government subsidies increased to RMB 53,864 thousand in 2023, compared to RMB 44,871 thousand in 2022[25] - Interest income rose significantly to RMB 47,491 thousand in 2023 from RMB 13,159 thousand in 2022[25] - Other income, including government subsidies and interest income, totaled RMB 102,963 thousand in 2023, up from RMB 68,712 thousand in 2022[25] - Foreign exchange gains in 2023 amounted to RMB 1,091 thousand, compared to a loss of RMB 14,446 thousand in 2022[27] - The fair value gain on financial assets measured at fair value through profit or loss was RMB 29,329 thousand in 2023, compared to a loss of RMB 8,281 thousand in 2022[27] - Total other income or net loss for 2023 was RMB 30,927 thousand, a significant improvement from a net loss of RMB 23,378 thousand in 2022[27] - Pre-tax profit for 2023 was RMB 1,745,089 thousand, up from RMB 1,177,749 thousand in 2022[32] - Government subsidies in 2023 totaled RMB 53,864 thousand, compared to RMB 44,871 thousand in 2022[28] - Employee benefits expenses increased to RMB 115,492 thousand in 2023 from RMB 75,777 thousand in 2022[28] - Total tax expenses for 2023 were RMB 296,887 thousand, up from RMB 176,163 thousand in 2022[31] Product and Market Performance - The company operates as a single business segment focused on the development, manufacturing, and sale of beauty and health products based on bioactive ingredients[17] - Revenue from sales of goods is recognized at the point when control of the asset is transferred to the customer, typically upon delivery[24] - The company has no major customers contributing more than 10% of total revenue in 2023[20] - The company led the drafting and release of industry standards for recombinant collagen protein in 2023, including the first group standard for cosmetic use[53] - The company has over 100 product SKUs as of the end of the reporting period[54] - The collagen dressing product maintained its position as the top-selling product in the wound dressing category on Tmall and the medical beauty category on JD during the 618 and Double 11 promotions[54] - The collagen stick product achieved a GMV growth of over 700% during the 618 promotion and over 200% during the Double 11 promotion[55] - The collagen stick ranked first in the annual essence gold list on Douyin and the family care category on JD during the 618 promotion[55] - The collagen stick ranked first in the facial essence category on Tmall and the family care single product category on JD during the Double 11 promotion[55] - The collagen milk product ranked first in the Tmall new product list for lotions from March to April and in the top 3 of the Tmall repair lotion list from August to September[55] - The collagen milk product ranked first in the Douyin repair essence lotion list and eighth in the Douyin cream hot-selling list during the Double 11 promotion[55] - The collagen soothing patch product was awarded the Douyin Top 100 Beauty Products Gold List - Home Beauty Salon 2023 Gold List Single Product[55] Corporate Social Responsibility and Awards - The company donated over RMB 1 million worth of supplies to nearly 20,000 educators in March 2023 as part of its corporate social responsibility initiatives[64] - The company was awarded the title of "National Quality Integrity Benchmark Enterprise" and "National Recombinant Collagen Protein Industry Quality Leading Enterprise" in October 2023[63] - The company was recognized as a "Shaanxi Province Green Factory" for its achievements in green manufacturing and sustainable development[63] Employee and Shareholder Plans - The company had 1,164 full-time employees as of December 31, 2023, with 33.8% in production, 14.2% in R&D, 33.5% in sales and marketing, and 18.5% in general and administrative roles[94] - The company adopted a Restricted Stock Unit (RSU) plan in December 2021, with a maximum of 19,000,000 shares, representing approximately 1.91% of the total issued share capital[96] - The 2023 Share Option Plan and 2023 Share Award Plan allow for the issuance of up to 99,500,000 shares, representing 10% of the total issued shares[96] Financial and Operational Risks - The company had no outstanding bank loans or borrowings as of December 31, 2023, resulting in a capital-to-debt ratio of 0%[85] - As of December 31, 2023, the company had no significant contingent liabilities[91] - The company did not engage in any purchase, sale, or redemption of its listed securities during the reporting period[97] Global Offering and Proceeds Utilization - Global offering net proceeds amounted to approximately HKD 573.7 million, allocated as follows: 11% for R&D investment, 28% for production capacity expansion, 46% for sales and distribution network enhancement, 5% for operational and information system upgrades, and 10% for working capital and general corporate purposes[102] - As of December 31, 2023, the company has utilized HKD 383.6 million of the net proceeds, with HKD 173.4 million remaining, expected to be fully utilized by December 31, 2027[104] Market Expansion and Retail Presence - The company launched its first offline standard store for Kefumei in Xi'an in November 2023, and opened 3 Kelijing stores in Xi'an from May to December 2023[60] - The company's story film "Component China" achieved a total exposure of over 500 million across all platforms[59] - The company conducted over 1,000 training and exchange activities for hospitals and pharmacies during the reporting period[60]

Financial Performance - For the six months ended June 30, 2023, the company's revenue reached RMB 1,605.7 million, representing a 63.0% increase compared to RMB 984.9 million in the same period of 2022[9]. - Gross profit for the same period was RMB 1,351.0 million, up 61.2% from RMB 838.3 million year-on-year[9]. - The company's profit before tax was RMB 775.6 million, reflecting a 51.2% increase from RMB 513.1 million in the previous year[9]. - Net profit for the six months ended June 30, 2023, was RMB 666.0 million, a 52.3% increase from RMB 437.2 million in the same period of 2022[47]. - Basic earnings per share increased by 48.9% to RMB 0.67, while diluted earnings per share rose by 61.0% to RMB 0.66[48]. Revenue Breakdown - Revenue from professional skincare products was RMB 1,197.0 million, accounting for 74.5% of total revenue, up from 62.4% in the previous year[27]. - Revenue from the Kefu Mei brand reached RMB 1.228 billion, representing a growth of 101.0% compared to the same period in 2022[18]. - The Keli Jin brand achieved revenue of RMB 321 million, reflecting a growth of 6.4% compared to the same period in 2022[19]. - Revenue from health food and other products was RMB 10.9 million, a decrease from RMB 24.1 million in the previous year[27]. - Revenue from sales to distributors was RMB 522.6 million, a 10.2% increase year-on-year, accounting for 32.5% of total revenue[32]. Research and Development - Research and development expenses amounted to RMB 34.0 million, an increase of 80.8% year-on-year, with R&D spending accounting for 2.1% of revenue, up 0.2 percentage points[12]. - The company has authorized and applied for a total of 86 patents, with 6 new patents added during the reporting period[13]. - The company launched several self-developed raw materials for new products, including a rare ginsenoside CK monomer with significant anti-inflammatory effects[14]. - The company is leading the establishment of industry standards for recombinant collagen protein materials in the cosmetics sector, marking a milestone in the standardization of this industry[13]. Assets and Equity - The total assets of the company as of June 30, 2023, were RMB 3,878.0 million, a 23.6% increase from RMB 3,138.2 million at the end of 2022[10]. - The total equity increased to RMB 3,517.5 million, up 24.0% from RMB 2,837.0 million at the end of 2022[10]. - As of June 30, 2023, the company's current assets amounted to RMB 1,557.5 million, a 17.0% increase from RMB 1,331.0 million at the end of 2022[58]. Sales and Marketing - The direct sales channel generated revenue of RMB 1.083 billion, accounting for 67.5% of total revenue, while the distribution channel contributed RMB 523 million, making up 32.5%[22]. - During the 618 promotional event, the Kefu Mei collagen stick sold over 35 million units, with GMV increasing by over 700% year-on-year[17]. - The Kefu Mei brand's collagen dressing was ranked TOP1 in the Tmall wound dressing category during the 618 event[16]. - The company expanded its sales network to approximately 1,400 public hospitals and 2,200 private hospitals and clinics across China[22]. Operational Efficiency - The company continues to expand its production capacity to strengthen its end-to-end manufacturing capabilities[11]. - The company added 2 new collagen production lines, 2 cosmetic production lines, and 1 medical device production line during the reporting period[23]. - The company aims to improve operational efficiency and user engagement through refined channel operations and content marketing strategies[25]. Cash Flow and Investments - Net cash from operating activities for the six months ended June 30, 2023, was RMB 692,895 thousand, significantly up from RMB 311,408 thousand in the same period of 2022, indicating an increase of about 122%[105]. - Cash flow from investment activities for the six months ended June 30, 2023, was a net outflow of RMB 472,404 thousand, compared to a net outflow of RMB 175,761 thousand in 2022[106]. - The company incurred RMB 186,961 thousand in capital expenditures for property, plant, and equipment during the six months ended June 30, 2023, compared to RMB 42,605 thousand in 2022[106]. Corporate Governance - The board of directors has adopted corporate governance practices in compliance with applicable codes, although it has not separated the roles of chairman and CEO[69]. - The company has adopted a restricted share unit plan allowing for a maximum of 19,000,000 shares to be granted, representing approximately 1.91% of the total issued share capital[66]. - The company aims to align employee incentives with shareholder interests through the restricted share unit plan[82]. Employee and Management - The company has a total of 1,023 full-time employees as of June 30, 2023, with 36.7% in production, 13.0% in R&D, 33.0% in sales and marketing, and 17.3% in general and administrative roles[64]. - The total remuneration for key management personnel was RMB 9,185 thousand for the six months ended June 30, 2023, compared to RMB 7,591 thousand for the same period in 2022, reflecting a 21.0% increase[133].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 GIANT BIOGENE HOLDING CO., LTD 巨 子 生 物 控 股 有 限 公 司 （於開曼群島註冊成立的獲豁免有限公司） 2367 （股份代號： ） 2023 6 30 截 至 年 月 日 止 六 個 月 的 中 期 業 績 公 告 財務摘要 6 30 截至 月 日止六個月 2023 2022 年 年 變動 人民幣百萬元人民幣百萬元 1,605.7 984.9 63.0% 收入 1,351.0 838.3 61.2% 毛利 775.6 513.1 51.2% 稅前利潤 666.0 437.2 52.3% 淨利潤 歸屬於母公司持有者 666.9 437.2 52.5% 盈利 ...

Financial Performance - Total revenue for 2022 reached RMB 2,364.4 million, representing a 52.3% increase from RMB 1,552.5 million in 2021[9] - Gross profit for 2022 was RMB 1,995.2 million, up 47.3% from RMB 1,354.3 million in the previous year[9] - Profit before tax increased to RMB 1,177.7 million, a 21.1% rise compared to RMB 972.9 million in 2021[9] - Net profit for the year was RMB 1,001.6 million, reflecting a 21.0% growth from RMB 828.1 million in 2021[9] - Earnings attributable to equity holders of the parent amounted to RMB 1,002.0 million, a 21.0% increase from RMB 828.1 million in the prior year[9] - Adjusted net profit (non-IFRS measure) was RMB 1,056.4 million, up 24.1% from RMB 851.3 million in 2021[9] - Basic earnings per share for 2022 were RMB 0.99, compared to RMB 0.83 in 2021, marking a 19.3% increase[9] - Total assets as of December 31, 2022, were RMB 3,138.2 million, compared to RMB 2,651.1 million in 2021[11] - Total liabilities stood at RMB 301.2 million, a significant decrease from RMB 6,861.4 million in 2021[11] - Total equity reached RMB 2,837.0 million, up from RMB 1,016.8 million in the previous year[11] Revenue Breakdown - Revenue from professional skincare products reached RMB 1,561.6 million, accounting for 66.0% of total revenue, up from RMB 861.1 million (55.5%) in 2021[34] - Revenue from medical dressings was RMB 760.1 million, representing 32.2% of total revenue, compared to RMB 642.0 million (41.3%) in 2021[34] - The company's direct sales channel generated revenue of RMB 1,401.8 million, accounting for 59.3% of total revenue, while the distributor channel contributed RMB 962.6 million, making up 40.7%[26] - Sales revenue for the professional skincare product "可復美" reached RMB 1,613.0 million, an increase of 79.7% compared to 2021, accounting for 68.2% of total revenue in 2022[45] - "可麗金" generated sales revenue of RMB 618.4 million, up 17.6% from 2021, representing 26.2% of total revenue in 2022[46] - Other brands contributed RMB 90.3 million in sales revenue, a 13.8% increase from 2021, making up 3.8% of total revenue in 2022[47] - Sales revenue from health food and other products was RMB 42.7 million, a decrease of 13.7% from 2021, accounting for 1.8% of total revenue in 2022[48] Research and Development - Research and development (R&D) expenses increased by 76.5% year-on-year, totaling RMB 440 million, with an R&D expense ratio of 1.9%[18] - The company has applied for and authorized 80 patents, with 27 new patents added in 2022[18] - The company is involved in 4 national key research projects and 2 national high-tech research and development plans[18] - The company plans to enhance R&D investment in synthetic biology and develop new recombinant collagen and other bioactive ingredients[1] Sales and Marketing Strategy - The company has expanded its sales channels to over 1,300 public hospitals, approximately 2,000 private hospitals and clinics, and around 500 chain pharmacy brands in China[13] - The company has established a dual-track sales strategy targeting both medical institutions and the general consumer market, ensuring effective user engagement[27] - The company’s direct-to-consumer (DTC) sales primarily occur through e-commerce platforms, including Tmall, JD.com, Douyin, Xiaohongshu, and Pinduoduo[27] - The company emphasizes sustainable production practices, utilizing synthetic biology methods to reduce environmental impact and resource consumption[27] Corporate Governance - The company has a strong governance structure with members on the audit, nomination, and corporate governance committees[101] - The board consists of four executive directors and three independent non-executive directors, meeting the requirement of having at least one-third of the board as independent[109] - The company has established an audit committee consisting of independent non-executive directors to oversee financial reporting and risk management[121] - The company has implemented a corporate governance policy and practices, which are regularly reviewed and updated[126] Employee and Shareholder Relations - The company employed 933 full-time employees as of December 31, 2022, primarily located in Shaanxi Province, China[76] - The company has implemented a comprehensive training program for new hires and internal transfers to ensure employee competency[77] - The company provides competitive compensation and performance cash bonuses as part of its HR strategy to retain talent[77] - The company emphasizes effective communication with shareholders to enhance investor relations and transparency[149] Environmental, Social, and Governance (ESG) - The company’s first Environmental, Social, and Governance (ESG) report highlights its management practices and performance in economic, environmental, social, and governance aspects[156] - The report is prepared in accordance with the Hong Kong Stock Exchange's guidelines, ensuring the completeness, substance, authenticity, and balance of the information disclosed[157] - The company has established ESG performance indicators covering waste emissions, greenhouse gas emissions, energy usage, and quality safety[167] - The company has not reported any incidents of corruption or bribery during the reporting period[175] Risk Management - The company has established a risk management and internal control system to address identified risks, which includes regular assessments and updates[139] - The company plans to provide ongoing training for directors and senior management regarding relevant Chinese laws and regulations to proactively identify compliance issues[140] - The company has a governance committee that reviews corporate governance and ESG policies[136] Quality Management - The company has established a comprehensive quality management system, ensuring product quality safety throughout the entire lifecycle, compliant with various international standards[186] - The company has implemented a three-line defense mechanism for risk management, involving all departments, internal audit, and the board of directors[183] - The quality department conducts inspections on intermediates, semi-finished products, and finished products, ensuring that non-conforming products are not released[198]